
How have antibody trends changed over the decades? Janice Reichert, Ph.D., founder and editor-in-chief of mAbs, joins host Paul Carter, Ph.D., to discuss the evolution of monoclonal antibody therapeutics and their experiences with shaping—and documenting—the field. Their conversation covers the advances that have transformed the industry, evolving success rates for antibody therapeutics, and the growing sophistication of multispecific antibodies, antibody-drug conjugates, and more. Plus, they...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Episode: 89 - James E. Crowe, Jr. on AHEAD 100, a New Strategy for Preparing for the Next Pandemic

Episode: 87 - Jack Elands on How Novel ADC Payloads Could Improve Cancer Care GUEST: Jack Elands, Ph.D., Founder and CEO, Adcytherix

Episode: 86 - PANEL DISCUSSION: Near-Term Challenges for ML/AI in Biotherapeutic R&D

Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating
Free AI-powered recaps of The Chain: Protein Engineering Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.